|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Datamonitor, June 2005, Pages: 205
The current ADHD market has long been saturated with traditional methylphenidate and amphetamine based drugs, with the only innovations being the development of extended release versions. However, the recent launch of Strattera (atomoxetine) has already shattered the traditional approach to drug therapy, opening the door for the uptake of new novel drug therapies.
Report Scope
Overview of the epidemiology, diagnosis and management of ADHD across the seven major pharmaceutical markets
Examination of the ADHD pipeline with in-depth clinical and commercial profiles of late-stage candidates, incorporating our opinion
Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2015
Insight and commentary from qualitative interviews with ADHD opinion leaders in the US and Europe
Report Highlights
The current global ADHD market is worth $2.7bn and is expected to reach $3.4bn by 2015, driven primarily by the launch of pipeline drugs and the continued growth of Strattera.
Innovation is key - manufacturers can no longer expect significant returns on standard extended release formulations. The current pipeline offers drugs with novel delivery mechanisms; improved durations of action and anti-abuse profiles, which will help differentiate these pipeline drugs from the current established ADHD therapies.
Although ADHD drugs have demonstrated significant efficacy in improving the three main symptoms of ADHD - inattention, hyperactivity and impulsivity - none have shown efficacy in treating the cognitive deficits of ADHD.
Reasons to Purchase
Understand unmet needs in the ADHD market based on opinion leader comments regarding both currently marketed and pipeline products
Benchmark key late-stage ADHD compounds against current market leaders
Assess the global sales forecasts of late-stage pipeline drugs for ADHD and examine their clinical and commercial potential'
Customers who bought this item also bought
Adult ADHD - Strattera Grows Up
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
Pipeline Insight: Hepatitis B - New Kids On The Block
Pipeline Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for innovation among me-toos
PharmaVitae 2004: Shire Pharmaceuticals US & Global Analysis
Pipeline Insight: Angiogenesis inibitors. Diversification and expansion of the innovatives class driving the evolution of cancer treatment
Pipeline Insight: Immunostimulators: Diversification and expansion of the innovatives class driving the evolution of cancer treatment
Pipeline Insight: Tumor-targeted agents: Diversification and expansion of the innovatives class driving the evolution of cancer treatment
|
|
|
|
